TET platform shows efficient T cell priming and beneficial safety profile Data supported clinical transition to ongoing TENDU Phase I trialTET platform offers potential to strengthen T cell response to
Ultimovacs Hosting Key Opinion Leader Webinar on the Evolving Treatment Landscape of Melanoma - read this article along with other careers information, tips and advice on BioSpace
Investegate announcements from Ultimovacs ASA, Ultimovacs to Present Preclinical Data on TET Platform at American Association for Cancer Research (AACR) 2022 Annual Meeting